Andreas D. Hartkopf
A5030131864- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Breast Lesions and Carcinomas
- Monoclonal and Polyclonal Antibodies Research
- Endometrial and Cervical Cancer Treatments
- Cancer survivorship and care
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Metastasis and carcinoma case studies
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- Endometriosis Research and Treatment
- Epigenetics and DNA Methylation
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Cancer-related cognitive impairment studies
- Cancer Diagnosis and Treatment
University Children's Hospital Tübingen
2009-2025
University of Tübingen
2016-2025
University Hospital Ulm
2016-2024
Universitätsklinikum Tübingen
2012-2024
Institut für Frauengesundheit
2016-2024
Universitäts Frauenklinik
2013-2024
Olgahospital
2024
Universität Ulm
2018-2024
Klinik Donaustauf
2024
Klinik für Frauenheilkunde
2022-2024
Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns TILs by histotype and relation to other clinical factors.
As the available information about breast cancer is growing every day, decision-making process for therapy getting more complex. ChatGPT as a transformer-based language model possesses ability to write scientific articles and pass medical exams. But it able support multidisciplinary tumor board (MDT) in planning of patients with cancer?
Abstract Background The phenotypes of tumor cells change during disease progression, but invasive rebiopsies metastatic lesions are not always feasible. Here we aimed to determine whether initially HER2-negative breast cancer (MBC) patients with HER2-positive circulating (CTCs) benefit from a HER2-targeted therapy. Methods open-label, interventional randomized phase III clinical trial (EudraCT Number 2010-024238-46, CliniclTrials.gov Identifier: NCT01619111) recruited March 2012 until...
Abstract Background Tumour size in breast cancer influences therapeutic decisions. The purpose of this study was to evaluate sizing primary using mammography, sonography and magnetic resonance imaging (MRI) thereby establish which method most accurately corresponds with the histological result. Methods Data from 121 patients were analysed a retrospective study. results divided into groups “ductal carcinoma situ (DCIS)”, invasive ductal (IDC) + “invasive (IDC)”, lobular (ILC)” “other tumours”...
Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in susceptibility genes and clinical relevance these are unclear. In this study, a prospective cohort mBC was used to determine mutation rates for (BC) predisposition genes, evaluate characteristics mutations, assess influence on patient outcome.
Abstract Background Circulating tumour cells (CTCs) are mainly enriched based on the epithelial cell adhesion molecule (EpCAM). Although it was shown that an EpCAM low-expressing CTC fraction is not captured by such approaches, knowledge about its prognostic and predictive relevance relation to EpCAM-positive CTCs lacking. Methods We developed immunomagnetic assay enrich from metastatic breast cancer patients independently using antibodies against Trop-2 CD-49f characterised their...
The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is interactive autonomous...
Pembrolizumab is approved for the neoadjuvant/adjuvant treatment of early triple-negative breast cancer (TNBC) patients in combination with chemotherapy. The Keynote-522 trial used platinum As neoadjuvant nab-paclitaxel (nP) also highly effective patients, this study investigates response to nP-containing chemotherapy pembrolizumab.NeoImmunoboost (AGO-B-041/NCT03289819) a multicenter, prospective single-arm phase II trial. Patients were treated 12 weekly cycles nP followed by four...
Abstract We aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and explore it other carcinoma histotypes. protein was assessed by clinical‐grade immunohistochemistry 6525 including 4334 HGSC using tissue microarrays from 24 studies participating Ovarian Tumor Tissue Analysis consortium. patterns were interpreted as abnormal (either overexpression referred block or absence) normal (heterogeneous). CDKN2A (which encodes p16) mRNA also...
In metastatic breast cancer (MBC), antigen profiles of tissue and primary tumor differ in up to 20 % patients. Reassessment predictive markers, including human epidermal growth factor receptor 2 (HER2) expression, might help optimize MBC treatment. While sampling is invasive often difficult repeat, circulating cell (CTC) analysis requires only a blood sample provide an easy-to-repeat, real-time “liquid biopsy” approach. The present retrospective study was conducted compare HER2 expression...
To prospectively assess circulating tumor cell (CTC) status at baseline (CTCBL) and after one cycle of a new line systemic therapy (CTC1C), changes from CTCBL to CTC1C (CTC kinetics, CTCKIN) for their utility in predicting response, progression-free (PFS) overall survival (OS) metastatic breast cancer (MBC). was determined as negative (-) or positive (+) < 5 ≥ CTCs/7.5 ml blood using CellSearch™ (Veridex). CTCKIN categorized favorable (CTC1C-) unfavorable (CTC1C+). Tumor response be assessed...
Abstract Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared other carcinomas. Nonetheless, current patient treatment continues to follow “one-size-fits-all” approach. Even though tumor staging offers stratification, personalized treatments remain elusive. As ENOC shares many clinical and molecular features its endometrial counterpart, we sought investigate The Cancer Genome Atlas–inspired (EC) subtyping in cohort of ENOC....
PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade (LGSOC)). We aimed to characterise expression as biomarker epithelial large population-based study.
PurposeTreatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients advanced hormone receptor–positive, HER2-negative (HR HER2–) breast cancer (BC). However, real-world data on the implementation of usage, efficacy, toxicity have not yet been reported.MethodsThe PRAEGNANT registry was used to identify HR HER2– BC (n = 1136). The use chemotherapy, ET, everolimus CDK4/6i ET analyzed first-line, second-line, third-line therapy. Progression-free survival (PFS)...
•Presence of CTCs in MBC is associated with worse clinical outcome.•About 15% patients HER2-negative harbor strong HER2 staining.•HER2 status predicts OS univariate but not multivariate analysis. BackgroundCirculating tumor cells (CTCs) have been reported to predict outcome metastatic breast cancer (MBC). Biology may differ from that the primary and HER2-positive are found some tumors.Patients methodsPatients were screened for participation DETECT III IV trials before initiation a new line...
Abstract Background Anthracycline/cyclophosphamide-taxane-containing chemotherapy (AC-T) is the standard of care in adjuvant treatment HER2-negative early breast cancer (EBC), but recent studies suggest omission anthracyclines for reduced toxicity without compromising efficacy. Methods Based on individual patient data ( n = 5924) pooled from randomised Phase III trials PlanB and SUCCESS C, we compared disease-free survival (DFS) overall (OS) between intermediate to high-risk EBC-patients...